本文選題：免疫檢查點(diǎn) + 腫瘤免疫　； 參考：《生理科學(xué)進(jìn)展》2017年04期

【摘要】：免疫檢查點(diǎn)(immune chenkpoint)是存在于免疫系統(tǒng)中的抑制性信號(hào)通路,對(duì)外周組織中免疫反應(yīng)強(qiáng)度、持續(xù)性予以調(diào)節(jié),防止組織損傷,并在維持自身抗原耐受性的過(guò)程中發(fā)揮作用。T細(xì)胞識(shí)別、清除腫瘤的過(guò)程受到諸多信號(hào)通路、配體/受體的嚴(yán)密調(diào)控。免疫檢查點(diǎn)療法就是一類(lèi)通過(guò)調(diào)節(jié)T細(xì)胞活性來(lái)提高抗腫瘤免疫反應(yīng)的治療方法。目前,通過(guò)抑制免疫檢查點(diǎn)阻斷信號(hào)以調(diào)節(jié)T細(xì)胞活性增強(qiáng)其抗腫瘤效應(yīng)是腫瘤治療熱點(diǎn),例如利用CTLA-4(cytotoxic T lymphocyte antigen4)、PD-1(programmed cell death1)、PD-L1(programmed cell death 1 ligand)的拮抗劑以及其它藥物干擾免疫檢查點(diǎn),可直接刺激細(xì)胞毒性T細(xì)胞的活化進(jìn)而啟動(dòng)抗腫瘤免疫,介導(dǎo)持續(xù)的腫瘤抑制過(guò)程。而聯(lián)合使用免疫檢查點(diǎn)阻斷劑加強(qiáng)腫瘤抑制效果也在進(jìn)行深入研究。免疫檢查點(diǎn)信號(hào)通路的生物學(xué)機(jī)制目前獲得諸多進(jìn)展,本文就一些已應(yīng)用于臨床的免疫檢查點(diǎn)及其它新型免疫檢查點(diǎn)的研究進(jìn)展加以綜述。
[Abstract]:Immune checkpoint (immune chenkpoint) is an inhibitory signaling pathway in the immune system. Immune response intensity in peripheral tissues is continuously regulated to prevent tissue damage. In the process of maintaining the tolerance of its own antigen, T cells can recognize and clear the tumor by many signal pathways, and the ligand / receptor is tightly regulated. Immune checkpoint therapy is a kind of treatment which can improve the anti-tumor immune response by regulating T-cell activity. At present, blocking the signal by inhibiting the immunological checkpoint to regulate the activity of T cells to enhance its anti-tumor effect is a hot topic in tumor treatment. For example, the antagonists of CTLA-4 cytotoxic T lymphocyte antigen4, PD-1programmed cell death1 and PD-L1programmed cell death 1 ligand, as well as other drugs, interfere with the immune checkpoint. It can directly stimulate the activation of cytotoxic T cells and initiate anti-tumor immunity and mediate the continuous tumor inhibition process. The combined use of immune checkpoint blockers to enhance tumor inhibition is also being further studied. Many advances have been made in the biological mechanism of immunological checkpoint signaling pathway. This article reviews the research progress of some immunological checkpoints and other new immunological checkpoints that have been applied in clinic.
【作者單位】： 大連理工大學(xué)生命與醫(yī)藥學(xué)院;
【基金】：國(guó)家自然科學(xué)基金(81672792) 遼寧省高等學(xué)校創(chuàng)新團(tuán)隊(duì)(LT2015008)資助課題
【分類(lèi)號(hào)】：R730.51
，

本文編號(hào)：1985829